Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC ...((pralatrexate) is a novel antifolate cur...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Date:10/25/2007
(pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent for which the Company expects to initiate a Phase 1 study in patients with advanced solid tumors in the second half of 2007. For additional information, please visit the Company's website at http://www.allos.com.
Safe Harbor Statement
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
concerning the Company's plans to initiate a Phase 2 study of PDX in
patients with NSCLC, and other statements which are other than statements
of historical facts. In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "expects,"
"intends," "plans," anticipates," "believes," "estimates," "predicts,"
"projects," "potential," "continue," and other similar terminology or the
negative of these terms, but their absence does not mean that a particular
statement is not forward- looking. Such forward-looking statements are not
guarantees of future performance and are subject to risks and uncertainties
that may cause actual results to differ materially from those anticipated
by the forward-looking statements. These risks and uncertainties include,
among others: that the Company may experience difficulties or delays in the
initiation, progress or completion of its clinical trials, whether caused
by c
'/>"/>
| SOURCE Allos Therapeutics, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. The TripleMaster PCR System for three different amplifications
2. Cloning Based on Efficient Three-Fragment Assembly DNA Ligation
3. Three Micron TSK-GEL ODS-100V Columns for High Throughput LCMS
4. Three finalists named for UW-Madison CIO
5. Three state businesses receive technology grants
6. Leading cancer institute to install three TomoTherapy systems
7. Waukesha considers wireless bids from three firms
8. Computerworld top 100 includes three Wisconsin CIOs
9. 30 days to success: Three simple steps to create your own international startup
10. Three firms get state tech development grants
11. Three more Wisconsin firms to present at venture forum
Post Your Comments:
Breaking Biology Technology:Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 334th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 234th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 3
[0] Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer[0] Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A[0] Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. [0] 34th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research
Other Biology Technology:Automation Alley Releases Report on State of Southeast Michigan's Technology Economy 2Automation Alley Releases Report on State of Southeast Michigan's Technology Economy 3Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH 2Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH 3deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke 2deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke 3deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke 4deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke 5
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Research is vital to a cleaner, greener, low carbon future 2China Nepstar Chain Drugstore Appoints Chief Operating Officer 47595 1China Nepstar Chain Drugstore Appoints Chief Operating Officer 47595 2China Nepstar Chain Drugstore Appoints Chief Operating Officer 47595 3Rules Based Medicine Inc Names Tony Barnes to Lead Expanding Diagnostics Business 47592 1Rules Based Medicine Inc Names Tony Barnes to Lead Expanding Diagnostics Business 47592 2Cardinal Health Increases Quarterly Dividend By 25 Percent 47589 1Cardinal Health Increases Quarterly Dividend By 25 Percent 47589 2Cardinal Health Increases Quarterly Dividend By 25 Percent 47589 3Cardinal Health Increases Quarterly Dividend By 25 Percent 47589 4
Other Biology News:Inhaling large amounts of salt can cause hypertension 2Newly discovered genetic disease sheds light on body's water balance 2Newly discovered genetic disease sheds light on body's water balance 3Newly discovered genetic disease sheds light on body's water balance 4Newly discovered genetic disease sheds light on body's water balance 5Understanding biases in epidemic models important when making public health predictions 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |